Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future

News
Article

Sponsored Content

In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.

Related Content
© 2024 MJH Life Sciences

All rights reserved.